Although female patentees are becoming more common – particularly in areas such as pharma and biotech – the rate of growth is slowing, suggesting that a lot more work needs to be done before equality between the sexes is achieved
Senior decision makers from a wide range of companies are already confirmed to attend as demand for tickets exceeds the rate for last year's sell-out event in San Francisco
Record-breaking Celgene purchase, two decisions on the on-sale bar, Europe moves towards SPC manufacturing waiver, China proposes five-year patent term extension and much more
The annual search for outstanding individuals to induct into the IP Hall of Fame starts today and we want your help.
The Federal Circuit’s precedential judgment in Supernus Pharmaceuticals v Iancu is good news for rights holders – especially those in life sciences
The Asia IP Elite identifies companies and institutions in the region that have world class IP functions. Here we introduce the 18 latest additions and explain why they have made the cut
SPC disputes, second medical use issues, pharma UPC strategies, CRISPR and much more from IAM’s third annual pharma and biotech IP conference, which took place in London earlier this week
America's life sciences innovators face accusations of using patents to build monopolies and overcharge for vital medicines. If they do not tell their side of the story and fast, they risk losing vital protections on which they rely
Law and attorney firms from around the world recognised for their outstanding work in litigation, prosecution and transactions during 2018
In exclusive interview with IAM, after confirming as a speaker for IPBC Global 2019, the former BlackBerry IP chief talks in-depth about life sciences and high tech convergence - and the many patent opportunities that creates
New IAM research reports identify the key trends shaping the global IP market – and tell you how to respond
The $1 billion deal emphasises that for IP professionals a detailed understanding of data-related issues is set to become essential
The rise of disruptive new technology means that everything you thought you knew about making money from IP is set to change
Services at the FDA could “grind to a halt” in a matter weeks if the budget deadlock between President Trump and Democrats continues. Major disruption at the USPTO and in the courts may also be on the cards.
IAM Market teams up with Richardson Oliver Insights to deliver new tranche of assets to its IP buying, selling, licensing and tech transfer platform being offered by top brokers